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Killed but Metabolically Active Leishmania infantum as a Novel
Whole-Cell Vaccine for Visceral Leishmaniasis
Kevin W. Bruhn,a,d Ron Birnbaum,a Jacquelyn Haskell,a Veena Vanchinathan,a Stephanie Greger,a Rupa Narayan,a Pei-Lin Chang,a
Thu Anh Tran,a Suzanne M. Hickerson,b Stephen M. Beverley,b Mary E. Wilson,c and Noah Crafta,d
Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles Medical Center, Torrance, California, USAa; Department of Molecular
Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USAb; Departments of Internal Medicine, Epidemiology and Microbiology, University of
Iowa and the Veterans Affairs Medical Center, Iowa City, Iowa, USAc; and David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California,
USAd
There are currently no effective vaccines for visceral leishmaniasis, the secondmost deadly parasitic infection in the world. Here,
we describe a novel whole-cell vaccine approach using Leishmania infantum chagasi promastigotes treated with the psoralen
compound amotosalen (S-59) and low doses of UV A radiation. This treatment generates permanent, covalent DNA cross-links
within parasites and results in Leishmania organisms termed killed but metabolically active (KBMA). In this report, we charac-
terize the in vitro growth characteristics of both KBMA L. major and KBMA L. infantum chagasi. Concentrations of S-59 that
generate optimally attenuated parasites were identified. Like live L. infantum chagasi, KBMA L. infantum chagasi parasites were
able to initially enter liver cells in vivo after intravenous infection. However, whereas live L. infantum chagasi infection leads to
hepatosplenomegaly in mice after 6 months, KBMA L. infantum chagasi parasites were undetectable in the organs of mice at this
time point. In vitro, KBMA L. infantum chagasi retained the ability to enter macrophages and induce nitric oxide production.
These characteristics of KBMA L. infantum chagasi correlated with the ability to prophylactically protect mice via subcutaneous
vaccination at levels similar to vaccination with live, virulent organisms. Splenocytes frommice vaccinated with either live L.
infantum chagasi or KBMA L. infantum chagasi displayed similar cytokine patterns in vitro. These results suggest that KBMA
technology is a potentially safe and effective novel vaccine strategy against the intracellular protozoan L. infantum chagasi. This
approachmay represent a newmethod for whole-cell vaccination against other complex intracellular pathogens.
Leishmania species infect 2 million humans annually, and 70thousand die from the visceral formof leishmaniasis every year
(28). Transmission of Leishmania occurs following the bite of a
parasite-bearing phlebotomine sandfly, followed by uptake of in-
fectious metacyclic promastigotes by neutrophils and macro-
phages. Various disease manifestations, which depend upon the
species of infecting parasite and the genetics of the host (5), range
from self-resolving cutaneous lesions to potentially fatal visceral
infection of the liver, spleen, and bonemarrow (48). Resolution of
infection is associated with the induction of macrophage nitric
oxide (NO) (dependent upon inducible nitric oxide synthase
[iNOS]), gamma interferon (IFN-), reactive oxygen species
(ROS), and specificCD4 type 1 helper (Th1) andCD8 lympho-
cyte responses (25, 38). Leishmania species employ distinct mech-
anisms to elude effector arms of the immune system, including
inhibition of NO- and ROS-mediated macrophage killing and
phagolysosomal fusion, inhibition of cell-mediated immunity via
blocking of antigen presentation and cytokine production, and
recruitment of regulatory T cells or other interleukin-10 (IL-10)-
producing cells (6, 16, 30, 36).
Recent evidence supports the contention that sustained immu-
nity may require persistent low-level infection with parasites (2,
47). In some areas of endemicity, inoculation of live Leishmania
major parasites in the skin of at-risk individuals with the goal of
inducing amild infection and subsequent immunity is performed
(43, 44). However, this practice, termed leishmanization, has been
largely abandoned as unsafe as the vaccinating parasite retains
virulence and induces serious pathology at significant frequencies.
To overcome this problem, investigators are exploring the use of
genetically modified organisms that retain vaccinating potential
but lack the ability to reactivate or cause disease pathology (35, 39,
40, 46). Additional vaccination strategies in humans have included
heat-killed and parasite subunit vaccination along with adjuvants
such asMycobacterium bovis BCG, but none has resulted in an effec-
tive prophylactic vaccine (4, 10, 14, 18, 22, 23, 29).
Recently, our collaborators have developed a technology for kill-
ing organisms in blood products by treatment with micromolar
quantities of amotosalen hydrochloride (S-59), a DNA cross-linking
psoralen (12). Treatment with S-59, followed by UV type A (UVA)
light photoactivation, induces DNA monoadducts and interstrand
cross-links which block DNA replication and transcription by pre-
venting strand separation, resulting inmitotic arrest and eventual cell
death (49). DNA adduct number and pathogen inactivation effi-
ciency are directly related to S-59 concentration. This process effec-
tively kills multiple pathogens contaminating blood products, in-
cluding HIV, Plasmodium falciparum, and Leishmania, and is widely
used to sterilize blood products for human use (15, 26).
This same technology has also been applied as a strategy to
attenuate bacterial organisms so that theymay safely be utilized as
vaccines. The first microbe successfully attenuated was recombi-
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nant Listeria monocytogenes. When treated with nanomolar doses
of S-59 (plus UVA), Listeria bacteria were rendered replication
incompetent but remained metabolically active (8). This resulted
in Listeria that retained the ability to express heterologous anti-
gens of vaccine interest, invade mammalian cells, and stimulate
potent adaptive cellular immune responses. Similarly, psoralen
treatment ofBacillus anthracis and Salmonella enterica serovar Ty-
phimurium strains also resulted in replication-incompetent pop-
ulations capable of inducing protective immunity in small-animal
models (24, 41). We hypothesized that this approach, termed
killed but metabolically active (KBMA), might also have utility in
the intracellular, macrophage-tropic pathogen Leishmania. Here,
we describe the development of KBMA Leishmania species asso-
ciated with both cutaneous (L. major) and visceral (Leishmania
infantum chagasi) forms of leishmaniasis and demonstrate the fea-
sibility of this novel strategy of whole-cell vaccination against eu-
karyotic pathogens.
MATERIALS AND METHODS
Animals and parasites. Six- to eight-week-old female BALB/cmice (Jack-
son Laboratories) were used throughout. All experiments were approved
by the Institutional Animal Care and Use Committee at Los Angeles Bio-
medical Research Institute. Firefly luciferase-expressing L. major (L. ma-
jor-luciferase) promastigotes, derived from Friedlin (MHOM/JL/80/
Friedlin) clone V1, were engineered to express luciferase following
integration of the construct pIR1SAT-LUC-TK (B5113) into the rRNA
locus (45; also S. M. Hickerson and S. M. Beverley, unpublished data).
These L. major-luciferase parasites were routinely maintained at 26°C in
M199 (powder; Sigma)medium supplementedwith 1MHEPES (pH7.4),
10 mM adenine, 0.1% biotin, 0.25% hemin, 100 IU penicillin, 100 mg/ml
streptomycin, 10% fetal bovine serum, and 0.25 mg/ml biopterin. The L.
infantum chagasi strain MHOM/BR/00/1669 (previously known as Leish-
mania chagasi, and now considered synonymous with Leishmania infan-
tum [27])was originally isolated froma patient with visceral leishmaniasis
in northeast Brazil and was maintained by serial intracardiac injection in
outbred male golden hamsters. Hemoflagellate minimal essential me-
dium (HOMEM)was prepared as previously described (3). Promastigotes
were cultured inHOMEMat 26°C and passaged for nomore than 4weeks
before use in experiments. KBMA Leishmania parasites were prepared by
incubating stationary-phase promastigotes in 100 nM amotosalen (S-59)
for 1 h, followed by cross-linking of DNAwith 5.4 J/cm2 UVA irradiation
in an Intercept Illuminator (Cerus Corporation). Heat-killed organisms
were prepared by incubation in a 100°C bath for 10min. For carboxyfluo-
rescein succinimidyl ester (CFSE)-based experiments, L. infantum chagasi
promastigotes were stained with 5 M CFSE for 10 min, washed three
times with phosphate-buffered saline (PBS), and then cultured in
HOMEMfor the duration of in vitro experiments or resuspended in sterile
saline for in vivo experiments.
In vitro assays of parasite function. Parasite luciferase activity was
measured using a Luciferase Assay System (Promega) by sampling cul-
tures daily, lysingwith 5Reporter Lysis Buffer (Promega), andpromptly
measuring relative luminescence units (RLU) after luciferin addition us-
ing a Sirius Single Tube Luminometer (Berthold Detection Systems). In
vitro macrophage infection experiments were performed using murine
bone marrow-derived macrophages (BMDM) as described previously
(11), which were coincubated with promastigotes at a multiplicity of in-
fection (MOI) of 20 for 1 h before cultures were washed. Infection levels
were quantitated 48 h later by microscopy of Giemsa-stained cells. Mac-
rophage killing function, as measured by induction of nitric oxide pro-
duction, was determined by infecting BMDM with promastigotes. To
overcome Leishmania-induced macrophage suppression and thus induce
nitric oxide secretion, medium was supplemented with 10 units/ml re-
combinant murine IFN-. Supernatants were assayed by the Griess
method as previously described (34).
L.major footpad infections and bioluminescent imaging. For all in-
fection experiments, Leishmania promastigotes were grown to stationary
phase and then washed three times in PBS and resuspended in sterile
saline for injection into animals. Luciferase-expressing L. major promas-
tigotes were injected into footpads in 50-l aliquots at various concentra-
tions (see Fig. 1). Luciferase activity was measured by serial biolumines-
cent imaging at the indicated time points. Anesthetizedmicewere injected
intraperitoneally with 100 l of 3 mg/ml of the luciferase substrate, D-
luciferin, and imaged after 15 min in an IVIS 100 Imaging System (Xeno-
gen). Analysis of images was performed using Living Image software.
Mouse immunization and challenge with L. infantum chagasi. Live
or KBMA stationary-phase promastigotes (107/100l of saline) were sub-
cutaneously injected into the shaved dorsal-cervical area. Mice were im-
munized three times at 2-week intervals. Two or 8 weeks after the final
boost, mice were challenged intravenously with 107 stationary-phase pro-
mastigotes in 200 l of saline. These vaccination schedules and delays to
challenge were chosen to be consistent with existing models and with our
understanding of the development of adaptive immunity.
In vivo assay of mouse liver parenchymal infection. Twenty-four to
72 h following intravenous injection of CFSE-labeled parasites, BALB/c
mice were sacrificed, and livers were dissected. Single-cell suspensions
were prepared using glass slide maceration, and the homogenate was
passed through nylon mesh; CFSE-positive cells were quantitated by flow
cytometry on a FACSCalibur (BD) instrument.
Determination of organ parasite loads bymicroscopy and quantita-
tive PCR. Vaccinated mice were euthanized 4 weeks after infectious chal-
lenge. Livers and spleens were removed from challenged mice at the indi-
cated times and weighed. Multiple glass slide touch preparations of each
organ were Giemsa stained and microscopically assessed by a blinded
scorer. A minimum of 500 cells were counted for each slide. The number
of parasites/organ was calculated as the number of amastigotes per cell
nuclei times the organ weight (in mg) times 2  105, as previously de-
scribed (7, 50). To determine parasite loads by PCR, total genomic DNA
was harvested from livers and spleens using an UltraClean Tissue DNA
Isolation Kit (Mo Bio Laboratories). Quantitative PCR assays were then
performed using a TaqMan system (Applied Biosystems), with 200 nM
primers/probe and genomic DNA template diluted 1:10 following col-
umn elution. L. infantum chagasi parasite DNA and mouse DNA were
detected using primers specific for GP63 and tumor necrosis factor alpha
(TNF-), respectively. Primers and probeswere synthesized by Integrated
DNA Technologies (Coralville, IA) with the following sequences: GP63
for, 5=-GTA CGGCTG CGA CAC CTT-3=; GP63 rev, 5=-AGC CGAGGT
CCT GGA AGA T-3=; GP63 probe, 5=-/56-FAM-AGC CCG CAC CGC
CCT GGT-36-TAMSp-3= (where FAM is 6-carboxyfluorescein and
TAMsp is 6-carboxytetramethylrhodamine); TNF- for, 5=-TCC CTC
TCATCAGTTCTATGGCCCA-3=; TNF- rev, 5=-CAGCAAGCATCT
ATGCACTTAGACCC-3=; TNF-probe, 5=-/56-JOEN-TGGAGGAAG
GGC AGT TAG GCA TGG GA-3BHQ-2/-3= (where JOEN is 6-carboxy-
4=,5=-dichloro-2=,7=-dimethoxyfluorescein and BHQ is Black Hole
quencher). GP63 threshold cycle (CT) values below 35 were converted to
absolute parasite counts using previously determined standard curves and
were normalized to tissue DNA amounts by TNF CT values, as previously
described (9). GP63 CT values above 35 were considered to be below the
limit of detection, based on negative controls with no Leishmania DNA
template.
Flow cytometry and intracellular cytokine staining. CFSE-stained
parasites were sampled from culture flasks and analyzed by flow cytom-
etry. Splenocytes from immunized animals were cultured in complete
RPMI medium for 72 h in the presence of 10 units/ml of recombinant
mouse IL-2 (BD) and 3  106 live promastigotes as an antigenic stimu-
lant. In the final 6 h of culture, medium and promastigotes were supple-
mented with 1 l/ml GolgiPlug (containing brefeldin A; BD). Cells were
stained with CD4-phycoerythrin (PE) (clone RM-45; BD) or CD8-PE
(clone 53-6.7; BD) antibodies at a final concentration of 5 g/ml, perme-
abilized using a Cytofix/CytopermKit (BD) according to themanufactur-
KBMA Leishmania as a Visceral Leishmaniasis Vaccine
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er’s instructions, stained intracellularly with IFN-–fluorescein isothio-
cyanate (FITC) (clone XMG1.2; BD) (final concentration of 2 g/ml),
and analyzed on a FACSCalibur flow cytometer.
Luminexmultiplex cytokine analysis.Cell culture supernatants were
analyzed using a mouse Th1-Th2 panel (Bio-Rad) according to the man-
ufacturer’s instruction. Cytokines included IFN-, IL-12 (p70), IL-2,
IL-4, IL-5, and IL-10. Samples were analyzed on a Luminex 200 instru-
ment. Data were analyzed with BeadView software (Upstate).
Statistical methods. Experiments were analyzed by two-tailed t tests.
Unless stated otherwise, a P value of0.05 was considered significant.
RESULTS
Characterization of KBMA Leishmania. We hypothesized that
species of Leishmania, a eukaryotic protozoan pathogen, could be
rendered replication incompetent while retaining functional and
immunogenic characteristics relevant to host infection, as previ-
ously achieved with various killed but metabolically active bacte-
rial strains (8, 24, 41). To test this hypothesis, we utilized strains of
L. major and L. infantum chagasi, agents of cutaneous and visceral
leishmaniasis, respectively. Use of transgenic strains of Leishma-
nia engineered to express the firefly luciferase gene (45) allowed us
to monitor the progression of both in vivo infections and in vitro
cultures of parasites. We first assessed the ability of killed but
metabolically active (KBMA) parasites to establish infection in a
footpad model of cutaneous leishmaniasis. Luciferase-expressing
L. major promastigotes were treated with various doses of S-59
followed by UVA illumination to induce stable DNA cross-links.
Increasing numbers of untreated promastigotes or a fixed number
of promastigotes (107) treated with increasing doses of S-59 (plus
UVA) were injected into the footpads of BALB/c mice, and the
course of infection was followed by serial bioluminescent imaging
(Fig. 1). Each footpad shown in this figure received a different
inoculum or S-59 dose. Inoculation with untreated promastigotes
(panel A) led to progressive footpad swelling, ulceration, and lu-
ciferase production. Infections were detectable at earlier time
points postinfectionwith higher numbers of parasites in the initial
inoculation (Fig. 1A). In comparison, inoculations of 107 L. major
promastigotes (similar to the right-most footpad shown in panel
A) treatedwith increasing doses of S-59 (plusUVA) all established
initial infections, but doses of 100 nM S-59 and above resulted in
progressive diminution of luminescence to low levels by day 8
(panel B). Promastigotes treated with only 10 nM S-59 caused a
FIG 1 Treatment of Leishmania major promastigotes with S-59/UVA prevents progression of footpad infection. In the experiment shown in panel A, mice were
injected with the indicated numbers of live, untreated luciferase-expressing L. major promastigotes to determine the sensitivity of the assay to detect outgrowth
of live virulent parasites over time. Note that each individual footpad received a different inoculum of L. major. In the experiment shown in panel B, mice were
injected with 107 luciferase-expressing L. major promastigotes that had been pretreated with increasing doses of S-59 (plus UVA). Note that each individual
footpad was challenged with the same number of L. major parasites, but each inoculum of promastigotes had been treated with different doses of S-59.
Bruhn et al.
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progressive infection through day 29, which led to an ulcerating
lesion by day 43. There were no signs of swelling or infection in
footpads harboring L. major treated with the higher doses of S-59
at the end of 6 weeks. These data suggest that doses of S-59 of
100 nM, combined with UVA irradiation, render L. major
highly attenuated, reducing the infectious equivalent by a factor of
at least 104.
To further characterize the effects of this treatment on parasite
survival, we measured protein expression levels of S-59/UVA-
treated promastigote populations in liquid cultures grown over 3
weeks. Cultures of luciferase-expressing L. major were initially
seeded with various numbers of untreated promastigotes and
measured to establish baseline growth curves. Doses of S-59 (plus
UVA) of at least 100 nM induced a progressive decrease of meta-
bolic activity in cultures seededwith 107 treated L.major parasites.
Treatment of 107 promastigotes with 750 nM resulted in complete
inhibition of luciferase activity after 3 weeks (Fig. 2A). By com-
paring the growth curves of serial dilutions of untreated parasites
with growth curves of 107 L. major parasites treated with increas-
ing doses of S-59, one can estimate that 500 nM and 100 nM
resulted in inhibition of growth by factors of approximately 106
and 104, respectively (Fig. 2A). For example, 10 untreated para-
sites required the same amount of time to reach stationary phase
as 107 L.major promastigotes treatedwith 500 nMS-59. Addition-
ally, because confluent organisms expend all the nutrients in the
culture medium, downward drift of the number of RLU after 7 to
10 days at stationary phase is expected. Experiments with the vis-
ceral disease-causing species L. infantum chagasi yielded similar
results. Cultures of L. infantum chagasi promastigotes treatedwith
100 nMS-59 (plusUVA) lost all detectable luciferase activity by 21
days after initial seeding (Fig. 2B). To monitor replication follow-
ing S-59/UVA exposure, we stained live L. infantum chagasi with
CFSE and measured the intracellular concentration over time.
Promastigotes treated with 10 nM S-59 (plus UVA) replicated
only slightly more slowly than untreated controls (Fig. 2C). How-
ever, treatment with 100 nM S-59 (plus UVA) blocked nearly all
cellular division. For subsequent experiments, therefore, L. infan-
tum chagasi promastigotes were treated with 100 nM S-59 (plus
UVA); they are referred to here as KBMA L. infantum chagasi.
KBMA L. infantum chagasi parasites do not persist or cause
organomegaly in vivo. Virulent L. infantum chagasi parasites in-
jected into susceptible mouse strains replicate as amastigotes in
both liver and spleen, multiplying rapidly in the liver before even-
tual spontaneous clearance and progressing slowly in the spleen
(48). To determine the ability of KBMA L. infantum chagasi to
persist long-term in vivo, we intravenously injected five BALB/c
FIG2 Treatment of different species of Leishmaniawith S-59/UVA leads to extinction ofmetabolic activity and replication arrest in vitro. (A) Indicated numbers
of untreated L. major-luciferase promastigotes (black symbols) or 107 promastigotes treated with the indicated doses of S-59 (plus UVA) (green symbols) were
cultured in vitro and sampled for luciferase activity at the time points shown. Luminescence of each lysed culture sample is reported in relative light units (RLU).
(B) L. infantum chagasi-luciferase promastigotes were placed in culture at 107/ml following treatment with S-59 alone, UVA irradiation alone, or both, as shown.
Luminescence from lysed samples of each culture wasmeasured for the given time points. The threshold of detection (luminescence of PBS) is shown in red. (C)
L. infantum chagasi promastigotes were stained with CFSE and treated with 10 nMor 100 nM S-59 (plus UVA) on day 0 and assessed by flow cytometry for CFSE
levels at the time points shown. Controls were heat-killed promastigotes or untreated parasites (medium). HK, heat killed.
KBMA Leishmania as a Visceral Leishmaniasis Vaccine
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mice each with 107 untreated live or KBMA L. infantum chagasi
parasites. Six months after infection, all mice inoculated with live
L. infantum chagasi displayed marked hepatosplenomegaly, while
all of the KBMA L. infantum chagasi-inoculated mice had organ
sizes similar to uninfected mice (Fig. 3). Microscopic analysis of
Giemsa-stained tissue sections demonstrated liver and spleen par-
asite loads of 2.6  107  0.6  107 and 2.0  107  0.5  107
parasites per organ, respectively, in live L. infantum chagasi-in-
fected mice. No parasites, however, could be visualized micro-
scopically in any of the mice infected with KBMA L. infantum
chagasi. Quantitative PCR is a more sensitive method of detection
and demonstrated large parasite loads in the livers and spleens of
live L. infantum chagasi-infected animals. However, we were un-
able to detect any Leishmania DNA in the organs of KBMA L.
infantum chagasi-infected animals (data not shown). Thus, while
live L. infantum chagasi infection caused organomegaly and para-
site persistence inmouse liver and spleen 6months after infection,
KBMA L. infantum chagasi parasites were undetectable in tissues
at this time point, and KBMA L. infantum chagasi-infected ani-
mals showed no signs of associated organomegaly or detectable
parasite presence.
KBMA L. infantum chagasi parasites entermacrophages and
induce NO production. Leishmania are capable of infecting mac-
rophages both in vivo and in vitro. Entry of parasites into macro-
phages leads to induction of iNOS expression and secretion of NO
in macrophages primed with IFN- (17). To determine if KBMA
L. infantum chagasi parasites also induce a similar macrophage
response, we exposed primary murine bone marrow-derived
macrophages (BMDM) from BALB/c mice to Leishmania in vitro
and measured supernatant levels of NO. In the presence of exog-
enously added IFN-, KBMA L. infantum chagasi induced NO
production at levels similar to live L. infantum chagasi (Fig. 4A).
We performed similar infections of BMDM in the absence of ex-
ogenous IFN- to allow for the persistence of intracellular amas-
tigotes. Both live promastigotes and KBMA L. infantum chagasi
entered BMDM in vitro, transformed into amastigotes that were
FIG 3 Primary infection with KBMA L. infantum chagasi does not result in long-term organomegaly in mice. Groups of five mice each were intravenously
inoculated with either live or KBMA L. infantum chagasi promastigotes and 6 months later were euthanized. (A) Organs were removed and weighed. (B)
Representative spleens from inoculated mice are shown. KBMA L. infantum chagasi-infected animals had spleens that appeared normal after 6 months.
FIG 4 KBMA L. infantum chagasi parasites enter cells and induce NO. (A) BMDMwere infected with L. infantum chagasi promastigotes at an MOI of 20 in the
presence of 10 U/ml IFN-. Levels of NO production at 48 h are shown as a percent increase compared to IFN- stimulation alone. Bars represent the means of
three independent experiments, with standard errors of the means. (B) BMDM were infected with L. infantum chagasi promastigotes at an MOI of 20, with no
exogenous IFN- added. The percentage of infected macrophages was counted after 48 h. Bars represent means  standard errors of the means of triplicate
infections from a representative experiment. (C) Examples of infected Giemsa-stained cells from panel B. (D) CFSE-labeled L. infantum chagasi parasites were
treatedwith doses of 100 nMand 3,000 nMS-59 (plusUVA) or heat killed (HK) and injected intravenously into BALB/cmice. Twenty-four hours later liverswere
harvested, and single-cell suspensionswere analyzed by flow cytometry forCFSE positivity. Free parasites were excluded using forward scatter gating. Percentages
of cells containing CFSE-positive organisms are indicated within the gates. Results are representative of two independent experiments.
Bruhn et al.
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visible intracellularly by microscopy, and persisted intracellularly
at 48 h following infection, whereas heat-killed parasites were not
detectable at this time point (Fig. 4B and C). These results suggest
that KMBA L. infantum chagasi parasites are more similar to live
parasites than to heat-killed parasites in their ability to stimulate
significant NO production. Also, although infection rates are
slightly reduced compared to that with live parasites, KBMA L.
infantum chagasi parasites are able to entermacrophages and tem-
porarily persist intracellularly as amastigotes.
KBMA L. infantum chagasi parasites enter liver cells follow-
ing intravenous inoculation. To determine if KBMA L. infantum
chagasi parasites are able to infect macrophages in vivo, promasti-
gotes were stained with CFSE and injected intravenously into
BALB/c mice. Both live and S-59/UVA-treated parasites were de-
tected by flow cytometry in single-cell suspensions of livers from
mice 24 h following inoculation, whereas heat-killed organisms
were not readily detectable at this time point (Fig. 4D). The size of
the CFSE-positive events as determined by forward scatter indi-
cated that Leishmania parasites were associated with host cells
(data not shown). Infected cells (associated with both live para-
sites and KBMA L. infantum chagasi) were detectable at 72 h fol-
lowing infection as well (data not shown).
Prophylactic vaccination with KBMA L. infantum chagasi
protects against intravenous challenge with virulent L. infan-
tum chagasi. To determine the protective efficacy of KBMA L.
infantum chagasi vaccination, we performed vaccine/challenge ex-
periments in susceptible BALB/cmice. High-dose live L. infantum
chagasi injected subcutaneously in the dorsal neck has previously
been shown to partially protect mice against subsequent L. infan-
tum chagasi intravenous challenge (42). In our studies, animals
were injected subcutaneously with 107 live L. infantum chagasi or
KBMA L. infantum chagasi parasites or with saline and then
boosted with the same treatments twice more at 2-week intervals
before intravenous challenge with live, virulent L. infantum cha-
gasi 2weeks after the final immunization. Animals vaccinatedwith
KBMA L. infantum chagasi showed protection levels in the liver
similar to those of mice vaccinated with live L. infantum chagasi
(Fig. 5A). To determine whether vaccination effects were long
lasting, we repeated the experiment with 8 weeks between the last
vaccination and the infectious challenge (Fig. 5B). In both exper-
iments, control mice that were vaccinated subcutaneously with
virulent L. infantum chagasi orKBMA L. infantum chagasi, but not
challenged intravenously with virulent parasites, had no detect-
able parasites in the touch preparations after 1 month (data not
shown). Significant protection from virulent Leishmania chal-
lenge was induced by live and KBMA L. infantum chagasi vaccina-
tion regardless of the length of time after the last vaccination
boost.
Whole-cell KBMA vaccination induces adaptive CD4 im-
mune responses. To determine if vaccination with KBMA L. in-
fantum chagasi could induce adaptive immune responses against
Leishmania antigens, we measured T cell responses in the spleens
of vaccinated animals. Two weeks following vaccination as above,
groups of mice were sacrificed, and splenic T cells were restimu-
lated in vitro with live L. infantum chagasi for 3 days prior to
measuring intracellular IFN- levels.Mice in both live L. infantum
chagasi (3 of 3 animals) and KBMA L. infantum chagasi (2 of 3
animals) groups demonstrated Leishmania-specific T cell IFN-
responses above control mice (saline vaccinated) following re-
stimulation (Fig. 6A) although these differences were not statisti-
cally significant. All Leishmania-specific IFN--positive T cells de-
tected after this 3-day antigen exposure were also positive for the
surface marker CD4 but not for CD8 (data not shown). Using the
same cultured splenocytes from these groups of vaccinated mice,
we analyzed supernatants from Leishmania-restimulated spleno-
cytes for specific cytokines, using a multiplex cytometric bead ar-
ray. Splenocytes from animals vaccinated with either live or
KBMA L. infantum chagasi showed elevated mixed cytokine re-
sponses over saline-vaccinated animals (Fig. 6B). Splenocytes
from vaccinated animals demonstrated higher IFN- secretion
only when restimulated with Leishmania ex vivo. Overall, these
findings suggest that vaccination with KBMA L. infantum chagasi
can induce Leishmania-specific protective immune responses that
are functionally similar to those induced by live, fully virulent
Leishmania.
DISCUSSION
Successful vaccination with live, whole-cell organisms depends
upon safe, reliable attenuation coupled with retention of immu-
nogenicity. Several strategies to achieve this balance exist. Killed
pathogens alone often do not elicit long-lasting immunity, likely
due to their inability to access certain cellular compartments or
express virulence-associated genes. Some targeted gene deletion
strategies utilize live organisms that are nonpathogenic due to the
lack of defined virulence factors (35, 39, 40, 46), but these strains
can theoretically be prone to reversion to pathogenicity in vivo.
Here, we apply a novel method of attenuation to the eukaryotic
pathogen Leishmania, rendering the parasite unable to replicate.
However, KBMA parasites maintain functionality comparable to
live parasites during early stages of infection, before a progressive
diminution in metabolic activity. We demonstrate that L. infan-
tum chagasi parasites treated with S-59 psoralen and UVA irradi-
ation are capable of entering macrophages both in vitro and in
vivo, are able to make the complex life cycle transition from pro-
mastigote to amastigote form, and can activate macrophages to
produce microbicidal nitric oxide. When given as a subcutaneous
vaccine, KBMA L. infantum chagasi partially protects susceptible
FIG 5 Subcutaneous vaccination with KBMA L. infantum chagasi confers
protection tomice against challenge with virulent Leishmania.Groups of eight
mice each were vaccinated and boosted subcutaneously a total of three times,
every 2 weeks, with either live or KBMA L. infantum chagasi and then chal-
lenged intravenously with live, virulent L. infantum chagasi 2 weeks (A) or 8
weeks (B) later. Liver parasite burdens were measured 28 days following chal-
lenge by microscopic quantitation of Giemsa-stained liver preparations. Con-
trol mice that were vaccinated but not challenged intravenously with virulent
parasites had no detectable parasites by microscopy in the touch preparations
after 1 month (data not shown). Data are means  standard errors of the
means and are representative of two independent experiments.
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BALB/c mice from a virulent challenge of L. infantum chagasi to a
similar degree as live parasites. Both types of organisms elicit
splenocytes that display similar cytokine profiles in vitro. Impor-
tantly, unlike live L. infantum chagasi, KBMA L. infantum chagasi
parasites are avirulent and do not result in organomegaly or dis-
seminated infection when introduced intravenously in mice.
The ability to grow Leishmania promastigotes in culture al-
lowed us to directly assess the effects of KBMA treatment on in
vitro growth characteristics of two different Leishmania species.
The dose of S-59 (plus UVA) that inhibited luciferase expression
by day 21 in L. infantum chagasi (100 nM) did not completely
prevent outgrowth of a similar culture of L. major (Fig. 2A and B).
An identical dose of S-59 (plus UVA) significantly blocked prolif-
eration of L. infantum chagasi as measured by CFSE diminution
experiments (Fig. 2C). Although these in vitro assays suggest levels
of attenuation slightly less than 100% inactivation, similarly
treated KBMA Leishmania species were not detected in vivoweeks
ormonths following inoculation in either a cutaneousmodel (Fig.
1) or a visceral model (Fig. 3) of murine infection. Our results
suggest that significant levels of attenuation have been achieved to
prevent functional virulence and to justify additional research in
animal models. As shown in Fig. 3, KBMA attenuation results in a
significantly attenuated whole-cell vaccine. However, additional
safety measures should be explored as this approach is studied
further. Previous successful generation of KBMAbacterial species,
including Listeria monocytogenes, Salmonella enterica serovar Ty-
phimurium, and Bacillus anthracis (8, 24, 41), have incorporated
inactivation of nucleotide excision repair genes. Thus, these genes
could be targeted in the future for additional safety advantages
with little impact on immunogenicity.
There are several important differences between animal mod-
els of leishmaniasis and human disease. One important similarity,
especiallywith respect to cutaneous lesions, is that resolution of an
infection with live parasites results in lasting immunity. In con-
trast, inoculation with heat-killed Leishmania alone does not gen-
erally elicit long-lasting protection; in fact, heat-killed L. major
vaccination can actually be immunosuppressive when used in
mice previously immune to Leishmania (32). Heat-killed or pro-
tein preparations of Leishmania can be made more immunogenic
by the inclusion of adjuvant molecules, and repeated inoculations
of killed parasites can also generate anti-Leishmania immunity
(31). However, there are likely intrinsic differences between the
ways live parasites and killed parasites interact with the host to
determine subsequent immunity. The data presented here dem-
onstrate that S-59/UVA-treated promastigotes, which are signifi-
cantly attenuated by several measures in vitro and in vivo, have
similar protective and immunostimulatory profiles as live, viru-
lent promastigotes. Both live and KBMA L. infantum chagasi vac-
cination induces a mixed cytokine response including the Th1-
associated cytokines IFN- and IL-12, as well as the Th2-
FIG 6 Vaccination with KBMA L. infantum chagasi promastigotes induces Leishmania-specific splenic T cell responses. (A) Splenocytes from mice subcutane-
ously vaccinated with live or KBMA L. infantum chagasi parasites (as described in the legend of Fig. 5) were harvested 2 weeks after the final vaccination.
Single-cell spleen suspensions were stimulated in vitrowith live Leishmania parasites for 3 days in the presence of brefeldin A and assessed by flow cytometry for
intracellular IFN- production. Data are the means standard errors of the means (n 3 mice per group). (B) Splenocytes from mice vaccinated with live or
KBMA L. infantum chagasi were harvested 2 weeks after the final vaccination and cultured for 3 days in the presence of live L. infantum chagasi promastigotes
(black bars) or medium only (white bars). Supernatants from these cultures were analyzed for cytokine concentrations using a Luminex multiplex cytometric
bead assay. Bars show concentration of the relevant cytokine in pg/ml standard errors of the means (n 3 mice per group).
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associated cytokines IL-4, IL-5, and IL-10. This combination of
type 1 and type 2 cytokines may represent an initial in vivo im-
mune response that allows parasites to briefly persist; however,
this initial analysis of cytokine expression was carried out at a
single time point and is far from comprehensive. It does nonethe-
less suggest qualitative similarities between live andKBMA immu-
nization thatwill be interesting tomore fully characterize in future
studies.
The vaccination used as a positive control in visceral leishman-
iasis models in mice is a high-dose, subcutaneous inoculation of
live, virulent promastigotes. This approach does not lead to dis-
seminated parasites but confers a partial level of protection against
subsequent intravenous challenge. Leishmaniapromastigotes ren-
dered avirulent, either by long-term cultivation or by genetic de-
letion of the dihydrofolate reductase-thymidylate synthase
(DHFR-TS) gene locus, do not confer protection by this route
(42). The fact that KBMA organisms retain some characteristics
associated with virulence, especially during early infection, may
allow for increased levels of persistence and possibly allow for
prolonged antigen presentation. Durable immunity to reinfection
with L. major depends upon persisting parasites in the skin, which
are not completely cleared by the host, in part due to IL-10-pro-
ducing CD4 CD25 regulatory T cells (Tregs) (2, 47); however,
the role of parasite persistence in visceralizing forms of Leishma-
nia infection is not clear. Although our data demonstrate that
KBMA L. infantum chagasi parasites do not persist in mouse liver
and spleen 6 months following intravenous injection, it is not
known how long either live or KBMA organisms (or antigen) per-
sist following subcutaneous inoculation. This subcutaneous vac-
cination with either live or KBMA promastigotes induced protec-
tion against visceral disease for at least 8 weeks following
vaccination. As recent evidence suggests, the dosage and route of
inoculation challenge may influence immunity significantly (33).
Thus, further studies will be necessary to assess the longer-term
durability of the protection.
The KBMA strategy merits comparison with the strategy of
attenuating pathogens using ionizing radiation. Prophylactic im-
munization against experimental leishmaniasis using irradiated
promastigotes dates back to the studies ofHoward et al. andRivier
et al. (20, 37). One promising current candidate for a malarial
vaccine is an irradiated, metabolically active, nonreplicating P.
falciparum sporozoite (PfSPZ), under development by Sanaria
(13). Biochemically, a main distinction between the two ap-
proaches is that the psoralen-based strategy generates relatively
few permanent double-stranded DNA cross-links that prevent
replication by physically preventing strand separation, while ion-
izing radiation strategies induce broad DNA damage that inhibits
viability. It remains to be seenwhether this biochemical difference
will affect the ultimate immunogenicity of either vaccine method.
Our data demonstrate that KBMA-attenuated Leishmania strains
develop into the amastigote form inside macrophages. This find-
ing is similar to radiation-attenuated L. major promastigotes (1,
21, 37) and the P. falciparum sporozoite vaccine, both of which
demonstrate the ability to enter a target cell and undergo an initial
life cycle transformation. This process is likely important for over-
all immunogenicity.
The fact that some asymptomatic patients develop a protective
immune response after natural infection with Leishmania species
supports the case for development of safe, whole-cell vaccines.
Diverse host immune responses and the capacity of protozoa to
modify or vary their surface antigens suggest that a diverse anti-
genic repertoire in a vaccine may be required for widespread pub-
lic use. Given that over half the vaccines approved by the U.S.
Food and Drug Administration follow a live, attenuated, whole-
cell strategy (19), expanding the technological methods for this
general approach is worthwhile. The KBMA-based strategy pro-
vides the means to easily and broadly attenuate a population of
pathogenic microbes. This strategy could ultimately be combined
with more targeted attenuation strategies, such as deletion or
modification of specific virulence genes, which by themselves re-
sult in strains prone to reversion in vivo. Additionally, novel vac-
cine adjuvants might also provide a means to boost effector and
memory immune responses generated by attenuated whole-cell
vaccines. It is likely that the development of clinically useful vac-
cines will ultimately combine multiple strategies to provide the
necessary safety and efficacy for widespread human use. Ulti-
mately, many questions regarding both the safety and efficacy of
the KBMA approach must be addressed and investigated before
KBMA vaccines could be considered for use in humans. However,
we believe the data presented here support further research into
this method as a viable approach to generate attenuated, immu-
nogenic, and protective organisms for development into effective
vaccine platforms.
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